VILOXAZINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO3.ClH
Molecular Weight	273.756
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC1=C(OCC2CNCCO2)C=CC=C1

InChI

InChIKey=HJOCKFVCMLCPTP-UHFFFAOYSA-N

InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923 | https://www.ncbi.nlm.nih.gov/pubmed/324751 | http://bipolarnews.org/?tag=viloxazine | https://www.ncbi.nlm.nih.gov/pubmed/30924702

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 8297
Sodium-dependent noradrenaline transporter 38 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 8297

PubMed

Title	Date	PubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].	1986	3716711
Contribution of sleep research to the development of new antidepressants.	2005	16416706
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.	2005	16156382
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.	2005 Dec 9	16314157
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.	2006 Oct 20	16798119
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.	2007 May	17555643
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.	2009 Nov	18839201
Getting the balance right: Established and emerging therapies for major depressive disorders.	2010 Sep 7	20856599

Patents

Sample Use Guides

In Vivo Use Guide

100 mg

Route of Administration: Oral

Name

Type

Language

VILOXAZINE HYDROCHLORIDE

Official Name

English

VILOXAZINE HYDROCHLORIDE [USAN]

Common Name

English

Viloxazine hydrochloride [WHO-DD]

Common Name

English

2-[(O-Ethoxyphenoxy)methyl]morpholine hydrochloride

Common Name

English

SPN-812

Code

English

VILOXAZINE HYDROCHLORIDE [MART.]

Common Name

English

VILOXAZINE HCL

Common Name

English

(±)-MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-, HYDROCHLORIDE

Systematic Name

English

Qelbree

Brand Name

English

VIVALAN

Brand Name

English

VILOXAZINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

ICI-58834

Code

English

MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-, HYDROCHLORIDE

Systematic Name

English

ICI 58,834

Code

English

VILOXAZINE HYDROCHLORIDE [MI]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

2384